Page last updated: 2024-09-05

lapatinib and Malignant Mesothelioma

lapatinib has been researched along with Malignant Mesothelioma in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Maeda, A; Nakata, M; Nojima, Y; Okita, R; Saisho, S; Shimizu, K; Yukawa, T	1

Other Studies

1 other study(ies) available for lapatinib and Malignant Mesothelioma

Article	Year
Lapatinib enhances trastuzumab-mediated antibody-dependent cellular cytotoxicity via upregulation of HER2 in malignant mesothelioma cells. Oncology reports, 2015, Volume: 34, Issue:6 Topics: Animals; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Cell Line, Tumor; Cell Proliferation; Cetuximab; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Mice; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays	2015

Article

Year

Lapatinib enhances trastuzumab-mediated antibody-dependent cellular cytotoxicity via upregulation of HER2 in malignant mesothelioma cells.

Oncology reports, 2015, Volume: 34, Issue:6

Topics: Animals; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Cell Line, Tumor; Cell Proliferation; Cetuximab; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Mice; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays

2015